SCHEMBL6877141

SCHEMBL6877141

O=C1CN(Cc2ccc(-c3ccc4c(c3)CN(C3CC3)C4=O)cc2)C(=O)N1CC(F)F

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 3/20 0.39
GRM5 P41594 1/20 0.38
GRM1 Q13255 1/20 0.38
MAOA P21397 2/20 0.37
CYP2C9 P11712 1/20 0.36
ADRA1A P35348 1/20 0.36
HRH1 P35367 1/20 0.36
MCHR1 Q99705 1/20 0.36
LIPG Q9Y5X9 1/20 0.34
HDAC6 Q9UBN7 3/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
SCN1A P35498 1/20 0.34
SCN5A Q14524 1/20 0.34
SCN9A Q15858 1/20 0.34
HDAC4 P56524 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1817239 0.87 ENPP2 (0.39) ENPP2GRM5GRM1MAOACYP2C9
SCHEMBL6874779 0.86 ENPP2 (0.38) ENPP2GRM5GRM1MAOACYP2C9
SCHEMBL1815295 0.86 ENPP2 (0.53) ENPP2GRM5GRM1MAOACYP2C9
SCHEMBL6876204 0.85 GRM5 (0.39) ENPP2GRM5GRM1MAOACYP2C9
SCHEMBL6875893 0.85 MCHR1 (0.38) ENPP2GRM5GRM1MAOACYP2C9
SCHEMBL6874788 0.83 CYP2C9 (0.41) ENPP2GRM5GRM1MAOACYP2C9
SCHEMBL1819932 0.83 ENPP2 (0.41) ENPP2GRM5GRM1CYP2C9ADRA1A
SCHEMBL1817677 0.83 ENPP2 (0.40) ENPP2GRM5GRM1MAOACYP2C9
SCHEMBL6873688 0.82 HDAC1 (0.38) ENPP2HDAC6HDAC1HDAC2HDAC8
SCHEMBL1815307 0.79 ENPP2 (0.43) ENPP2GRM5GRM1CYP2C9ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507521-B2 Heterocyclic derivatives Merck Sharp + Dohme B.V. (NL) 2013-08-13 US disclosed
US-8507521-B2 Heterocyclic derivatives Merck Sharp + Dohme B.V. (NL) 2013-08-13 US disclosed
US-8507521-B2 Heterocyclic derivatives Merck Sharp + Dohme B.V. (NL) 2013-08-13 US disclosed
US-20120220622-A1 HETEROCYCLIC DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2012-08-30 US disclosed
US-20120220622-A1 HETEROCYCLIC DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2012-08-30 US disclosed
US-20120220622-A1 HETEROCYCLIC DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2012-08-30 US disclosed
WO-2011051490-A2 HETEROCYCLIC DERIVATIVES N.V. ORGANON (NL) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220622-A1 HETEROCYCLIC DERIVATIVES GRIN2C, GRIN3A, GRIN2D ENPP2 2659/4885GRM5 5/4885GRM1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.